Hospital Universitario La Fe Guide to the prophylaxis and treatment of fungal infections in immunodepressed patients or in patients requiring special care;Guía del Hospital Universitario La Fe para la profilaxis y el tratamiento de las infecciones fúngicas en los enfermos inmunodeprimidos o que requieren cuidados especiales

Revista Espanola de Quimioterapia

Volumn 17, Issue 4, 2004, Pages 357-389

  Jarque, I ^a   Salavert, M ^a   Roma E ^a   Gobernado, M ^a   Chiveli, M A ^a   Ruano, M ^a   Sole A ^a   Poveda, J L ^a   Ferrer, E ^a   Garcia Pellicer J ^a   Sanz, M A ^a   Peman J ^a   Sanchez V ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLUS; BLASTOMYCOSIS; BLOOD DISEASE; CANDIDA; COCCIDIOIDOMYCOSIS; CRYPTOCOCCUS NEOFORMANS; FUSARIUM; HISTOPLASMOSIS; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE DEPLETION; MYCOSIS; NEUTROPENIA; PNEUMOCYSTIS JIROVECI; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RHIZOPUS; RISK FACTOR; SCEDOSPORIUM; SOUTH AMERICAN BLASTOMYCOSIS; TRICHOSPORON; UNIVERSITY HOSPITAL;

ALGORITHMS; ANTIFUNGAL AGENTS; CLINICAL PROTOCOLS; CRITICAL CARE; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; PRACTICE GUIDELINES; RISK FACTORS;

EID: 19944429862     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Sociedad Española de Quimioterapia y Asociación Española de Hematología y Hemoterapia. Profilaxis y tratamiento de las infecciones fúngicas en el paciente oncohematológico. Rev Esp Quimioterap 2002; 15: 387-401.
2. Wald, A., Leisenring, W., van Burik, J.A., Bowden, R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
3. Walsh, T.J., Hiemenz, J., Pizzo, P.A. Evolving risk factors for invasive fungal infections - All neutropenic patients are not the same. Clin Infect Dis 1994; 18: 793-798.
4. Samonis, G., Kontoyiannis, D.P. Infectious complications of purine analog therapy. Curr Opin Infect Dis 2001; 14: 409-413.
5. Segal, B.H., Bow, E.J., Menichetti, F. Fungal infections in nontransplant patients with hematological malignancies. Infect Dis Clin North Am 2002; 16: 935-964
6. Bodey, G., Bueltmann, B., Duguid, W. y cols. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99-109.
7. Vogeser, M., Wanders, A., Haas, A., Ruckdeschel, G. A four-year review of fatal aspergillosis. Eur J Clin Microbiol Infect Dis 1999; 18: 42-45.
8. Berrouane, Y., Herwaldt, L.A., Pfaller, M.A. Trends in antifungal use and epidemiology of nosocomial yeast infections in a University Hospital. J Clin Microbiol 1999; 37: 531-537.
9. Viscoli, C., Girmenia, C., Marinus, A. y cols. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
10. Frasquet, J., Valentin, A., Aparisi, N. y cols. Cuatro años de candidemias en el Hospital La Fe (1998-2001). VI Congreso Nacional de Micología. Rev Iberoam Micol 2002; 19: Abstr. B01.
11. Jarque, I., Andreu, M., Salavert, M. y cols. Epidemiología de la candidemia en pacientes cou neoplasias hematológicas. Experiencia en un solo centro durante 16 años. VI Congreso Nacional de Micología. Rev Iberoam Micol 2002; 19: Abstr. B04.
12. Andreu, R., Llopis, I., Jarque, I. y cols. Infecciones fúngicas emergentes en pacientes hematológicos. VI Congreso Nacional de Micología. Rev Iberoam Micol 2002; 19: Abstr. B02.
13. Denning, D.W. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
14. Lin, S.J., Schranz, J., Teutsch, S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
15. Stevens, D.A., Kan, V.L., Judson, M.A. y cols. Infectious Diseases Society of America. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
16. Martino, R., Subirá, M. Invasive fungal infections in hematology: New trends. Ann Hematol 2002; 81: 233-243.
17. Ascioglu, S., Rex, J.H., de Pauw, B. y cols. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
18. Asociación Española de Micología. Guía práctica de identificación y diagnóstico en Micología Clínica. En: Pemán, J., Martín-Mazuelos, E., Rubio, M.C. (Eds.). Rev Iberoam Micol 2001.
19. Wingard, J.R., Leather, H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10: 73-90.
20. Gadea, I., Cuenca-Estrella, M., Grupos de Estudio MICOMED, GESITRA y SEIMC. Recomendaciones para el diagnóstico micológico y estudios de sensibilidad a los antifúngicos. Enferm Infecc Microbiol Clin 2004; 22: 32-39.
21. Del Palacio, A., Cuétara, M.S., Pontón, J. El diagnóstico de laboratorio de la aspergilosis invasora. Rev Iberoam Micol 2003; 20: 90-98.
22. Álvarez Lerma, F. Epidemiología de la infección fúngica en pacientes críticos. En: Alvarez Lerma, F. (Ed.). Infecciones fúngicas en pacientes críticos. Ergon, Madrid 2002; 7-22.
23. Álvarez Lerma, F. ¿Qué pacientes de UCI están en riesgo de padecer infecciones fúngicas profundas? ¿Cuándo debería utilizarse de forma empírica tratamiento antifúngico en el paciente ingresado en UCI? En: Aguado, J.M. (Ed). Temas a debate en enfermedades infecciosas: Infección fúngica. Drug-Pharma. Madrid 2003; 13-21.
24. León, C., Vicho, R., Loza, A., León. D. Indicaciones del tratamiento antifúngico en el paciente crítico. En: Alvarez Lerma, F. (Ed.). Infecciones fúngicas en pacientes críticos. Ergon, Madrid 2002; 73-83.
25. Speich, R., van der Bij, W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 2001; 33 (Suppl. 1): 58-65.
26. Rex, J.H., Sobel, J.D. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-1200.
27. Mehrad, B., Paciocco, G., Martinez, F.J. y cols. Spectrum of aspergillus infection in lung transplant recipients. Case series and review of the literature. Chest 2001; 119: 169-175.
28. Gavalda, J. ¿Cuáles son los factores de riesgo para el desarrollo de aspergilosis en un trasplante de órgano sólido? En: Aguado, J.M. (Ed.). Temas a debate en enfermedades infecciosas: Infección fúngica. Drug-Pharma, Madrid 2003; 215-220.
29. Muñoz, P., Bouza, E. ¿Cómo debe realizarse la profilaxis antifúngica en un trasplante de órgano so¿lido? En: Aguado, J.M. (Ed.). Temas a debate en enfermedades infecciosas: Infección fúngica. Drug-Pharma, Madrid 2003: 221-232.
30. Calvo, V., Borro, J.M., Morales, P. y cols., Valencia Lung Transplant Group. Antifungal prophylaxis during de early postoperative period of lung transplantation. Chest 1999; 115: 1301-1304.
31. Paya, C.V. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001; 33 (Suppl. 1): 47-52.
32. Drew, R.H., Palmer, S.M., Davis, R., Perfect, J.R. Invasive fungal infection (IFIs) in lung transplant recipients (LTR) receiving prophylactic aerosolized amphotericin B (aAmB) formulations. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California 2002; Abstr. M-1236.
33. Ruffini, E., Baldi, S., Libertucci, D. y cols. Aerosolized liposomal amphotericin B: A novel and effective treatment for Aspergillus infection in lung transplant recipients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California 2002; Abstr. M-1237.
34. Palmer, S.M., Drew, R.H., Whitehouse, J.D. y cols. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-548.
35. Corey, L., Boeckh, M. Persistent fever in patients, with neutropenia. New Engl J Med 2002; 346: 222-224.
36. Walsh, T.J., Pappas, P., Winston, D.J. y cols. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
37. Jonson, L.B., Kauffman, C.A. Voriconazole: A nev triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
38. Walsh, T., Sable, C., de Pauw, B. y cols. Trial of caspofungin vs liposomal amphotericin B for empirical antifungal therapy of patients with persistent febrile neutropenia. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA 2003; Abstr. M-1761.
39. Walsh, T.J., Finberg, R.W., Arndt, C. y cols. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
40. Amphotericin B. Drugdex Drug Evaluations. Drugdex® System. Drug Information. Micromedex computerized Clinical Information System®. Micromedex Inc., Greenwood Village, Colorado 2004; Vol. 119.
41. Walsh, T., Sable, C., de Pauw, B. y cols. A randomized, double-blind nmlticenter trial of caspofungin vs liposomal amphotericin B for empirical antifungals therapy of persistently febrile neutropenic patients. 43nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA 2003; Abstr. M-982.
42. Pfaller, M.A., Jones, R.N., Messer, S.A., Edmond, M.B., Wenzel, R.P., SCOPE Participant Group. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998; 30: 21-129.
43. Jarque, I., Saavedra, S., Martín, G., Pemán, J., Pérez Bellés, C., Sanz, M.A. Delay of onset of candidemia and emergence of Candida krusei fungemia in hematological patients receiving prophylactic fluconazole. Haematologica 2000; 85: 439-441.
44. Mora-Duarte, J., Belts, R., Rotstein, C. y cols. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
45. Blijlevens, N.M.A., Donnelly, J.P., de Pauw, B. Impared gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002; 117: 259-264.
46. Nucci, M., Anaissie, E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002; 34: 591-594.
47. Walsh, T.J., Rex J.H. All catheter-related candidemia is not the same: Assessment of the balance between the risks and benefitis of removal of vascular catheters. Clin Infect Dis 2002; 34: 600-602.
48. Kuhn, D.M., George, T., Chandra, J., Mukherjec, P.K., Ghannoum, M.A. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-1778.
49. Herbrecht, R., Denning, D.W., Patterson, T.F. y cols. Voriconazol versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
50. Maertens, J., Raad, I., Sable, C.A. y cols. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations, or azoles, En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 2002; Abstr. 1103.
51. Kirkpatrick, W.R., Perea, S., Coco, B.J., Patterson, T.F. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46; 2564-2568.
52. Perea, S., Gonzalez, G., Fothergill, A.W., Kirkpatrick, W.R., Rinaldi, M.G., Patterson, T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039-3041.
53. Shalit, I., Shadkchan, Y., Samra, Z., Osherov, N. In vitro synergy of caspofungin and itraconazole against Aspergillus spp: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother 2003; 47: 1416-1418.
54. Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
55. Rubin, M.A., Carroll, K.C., Cahill, B.C. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34: 1160-1161.
56. Tascini, C., Tagliaferri, E., Iapoce, R., Leonildi, A., Menichetti, F. Caspofungin in combination with itraconazole and amphotericin B for the treatment of invasive aspergillosis in humans, with a method to test ex vivo synergism. Clin Microbiol Infect 2003; 9: 901-902.
57. Kontoyiannis, D.P., Hachem, R., Lewis, R.E. y cols. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-299.
58. Elanjikal, Z., Sörensen, J., Schmidt, H. y cols. Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatr Infect Dis J 2003; 22: 653-656.
59. Aliff, T.B., Maslak, P.G., Jurcic, J.G. y cols. Refractory aspergillus pneumonia in patients with acute leukemia. Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97; 1025-1032.
60. Baddley, J.W., Stround, T.P., Salzman, D., Pappas, PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 20001; 32: 1319-1324.
61. Krcmery, V., Jr., Mateicka, F., Kunova, A. y cols. Hematogenous trichosporonosis in cancer patients: Report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer 1999; 7; 39-43.
62. Pagano, L., Girmenia, C., Mele, L. y cols. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMENA infection program. Haematologica 2001; 86: 862-870.
63. Boutati, E.I., Anaissie, E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
64. Girmenia, C., Pagano, L., Corvatta, L., Mele, L., del Favero, A., Martino, P. The epidemiology of fusariosis in patients with haematological diseases. GIMENA Infection Programme. Br J Haematol 2000; 11: 272-276.
65. Pagano, L., Ricci, P., Tonso, A. y cols. Mucormycosis in patients with haematological malignancies: A retrospective clinical study of 37 cases. GIMENA Infection Program. Br J Haematol 1997; 99: 331-336